We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib. (Korean J Med 2014;87:501-504) 
. T2-weighted magnetic resonance imaging of the brain showing bilateral symmetrical high-signal-intensity lesions in both temporal and parietal lobes. 중심 단어: Sunitinib; 저혈당; 대사성 뇌병증
